Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Peripheral blood TCR marker for cervical cancer as well as detection kit and application of peripheral blood TCR marker

A marker and cervical cancer technology, applied in the field of genetic engineering, can solve the problems that cannot be used as a basis for the diagnosis of cervical cancer, the effect is not good, and cannot be clearly displayed, so as to achieve the effect of reducing detection cost, low cost, and low labor cost

Pending Publication Date: 2020-09-11
CHENGDU EXAB BIOTECH CO LTD
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] (3) Abdominal and pelvic CT: Plain CT scan is not effective in observing local cervical lesions, especially early-stage lesions; enhanced CT scan is good for displaying local cervical lesions, but nearly 50% of the lesions are still isodense and cannot be clearly seen show
However, tumor markers can only serve as an aid in diagnosis and cannot be used as a basis for the diagnosis of cervical cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peripheral blood TCR marker for cervical cancer as well as detection kit and application of peripheral blood TCR marker
  • Peripheral blood TCR marker for cervical cancer as well as detection kit and application of peripheral blood TCR marker
  • Peripheral blood TCR marker for cervical cancer as well as detection kit and application of peripheral blood TCR marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1 Obtaining Cervical Cancer TCR Marker CDR3 Sequence Set by Immunogram Analysis

[0043] 1. Sampling and immune map analysis (method reference patent ZL201910300069.9)

[0044] Collect 1301 control groups (including healthy people and patients with non-tumor diseases, 1300 people for model building, 1 healthy person for verification), 101 patients with cervical cancer (100 people for model building, 1 person for verification) and the peripheral blood of a subject with unknown health status (10mL per person), and the amino acid sequence of the TCR epitope 3 (CDR3) of the subject and the control group was obtained by high-throughput sequencing to ensure the functionality of each sample The total number of CDR3 sequences of TCR should not be less than 30,000;

[0045] 2. The CDR3 sequence of the TCR of each sample is randomly sampled without replacement, so that the total number of CDR3 sequences of each sample is 30,000. For any specific CDR3 sequence X, the num...

Embodiment 2

[0051] Example 2 Verification of the specificity of the cervical cancer TCR marker CDR3 sequence set

[0052] 1. Sampling and immune map analysis (method reference patent ZL201910300069.9)

[0053] The peripheral blood (10 mL per person) of 250 non-cervical cancer patients and 30 subjects with unknown health status was collected, and the epitope 3 (CDR3) amino acid of the TCR of the subjects and the control group was obtained by high-throughput sequencing Sequences, to ensure that the total number of CDR3 sequences of functional TCRs in each sample is not less than 30,000; random non-replacement sampling is performed on the CDR3 sequences of TCRs in each sample, so that the total number of CDR3 sequences in each sample is 30,000.

[0054] 2. Randomly select 100 healthy people and 45 non-tumor disease patients from the control group in Example 1.

[0055] 3. According to 100 healthy people, 45 non-tumor disease patients, and 100 cervical cancer patients from embodiment 1, and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a peripheral blood TCR marker for cervical cancer as well as a detection kit and application of the peripheral blood TCR marker. The marker comprises at least one of proteins of which the sequences are shown as SEQ ID NO. 1-100. The method is based on a high-throughput sequencing method; only a small amount of peripheral blood needs to be collected; the method comprises thefollowing steps: extracting RNA, treating samples to establish an immune map library, carrying out high-throughput sequencing and TCR data analysis, firstly determining a characteristic TCR sequencein the peripheral blood of cervical cancer, and then comparing a test result of a sample to be tested with the characteristic TCR sequence so as to determine whether a patient suffers from the cervical cancer or not. According to the present invention, the huge number of the cervical cancer specific TCR sequences can be simultaneously compared, and compared to the single detection of one or more markers, the high specificity and the high accuracy are provided, and the diagnosis efficiency is improved.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering, and in particular relates to a peripheral blood TCR marker of cervical cancer, a detection kit and application thereof. Background technique [0002] According to the report of the 26th Chinese Cancer Prevention and Treatment Association of CGCS, there are about 500,000 new cases of cervical cancer each year (worldwide), and more than 80% of the cases occur in developing countries. There are about 130,000 new cases in my country every year, accounting for 28% of the total number of new cases in the world. According to the ICO China HPV and Related Diseases Report released in 2018, among Chinese women aged 15-44, the incidence of cervical cancer ranks third among malignant tumors, making it the second leading cause of cancer death in women. About 47,739 women died of cervical cancer in China in 2018. And the mortality rate of cervical cancer is on the rise, threatening the lives of C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574A61K39/00A61P35/00
CPCG01N33/57411G01N33/57488A61K39/001111A61P35/00G01N2333/7051A61K2039/892
Inventor 张志新杨鑫卓越钟雪梅杨诗涵高浩
Owner CHENGDU EXAB BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com